
物理性质
- 熔点127-128 °C
- 沸点402 °C
- 闪点11 °C
- 密度1.2±0.1 g/cm3
- pKa:4.66(at 30°C)
- PSA:52.04
- LogP:1.56
- 折射率1.667
- 蒸汽压0.0±0.8 mmHg at 25°C
- 溶解性Soluble In Ethanol (U.S. Epa, 1985) And Ether (1 G/50 Ml) (Windholz Et Al., 1983)
- 敏感性1.常温常压下稳定,避免强氧化剂、酸类、酸酐、酰基氯、氯仿。无色晶体,遇光或在空气中变黄色或红褐色。有剧毒,空气中浓度较高时,佩带防毒面具。紧急事态抢救或逃生时,应该佩带自给式呼吸器。戴安全防护眼镜。穿紧袖工作服,长统胶鞋。戴橡皮手套。易溶于醋酸和稀盐酸,溶于热水、微溶于水、乙醇、乙醚。与无机盐酸作用生成相应的盐。2.本品为联苯胺的衍生物。有毒。能刺激皮肤和黏膜。可致敏并可引起膀胱癌。应避免其与皮肤直接接触。生产设备要密闭,防止粉尘污染空气。操作人员应穿戴防护用具。
- 外观形态灰黄色结晶粉末;白色或微红色晶体、粉末
- 储存条件2-8°C
- 产品应用重要的染料中间体,联苯胺及其衍生物可用于制造直接染料,酸性染料,还原染料,冰染染料,硫化染料,活性染料及有机颜料.由联苯胺制成的染料约有250种以上,其中最重要的是直接黑EW,联苯胺黄为广泛应用的一种有机颜料.
- 性质描述白色或微淡红色结晶性粉末.熔点125°C,沸点400°C,(98.7kPa),相对密度1.250(20/4°C),易溶于沸乙醇,乙酸和稀盐酸,略溶于乙醚,微溶于沸水,极微溶于冷水.在空气和光线下颜色变深.分析试剂通常用溶解度较大的联苯胺盐酸盐或乙酸盐,工业上通常用硫酸盐.联苯胺乙酸盐为白色或近白色结晶,能溶于水,乙酸和盐酸,用作指示剂[36341-27-2].联苯胺盐酸盐[531-85-1].联苯胺硫酸盐为白色结晶粉末或小鳞片状结晶,溶于醚,极微溶于水,稀酸及醇[21136-70-9].
欧盟法规
《欧盟PIC法规》统一分类与标签ECHA物质食品接触材料-禁用CMR物质OtherC&L通报REACH预注册废弃物危险特性清单ECHA物质工作场所安全标识要求化妆品禁用物质清单欧盟化学试剂指令-附录三-禁令欧盟限制物质清单上下游产品
CAS号1528-74-1 4,4-二硝基联苯 | CAS号106-40-1 对溴苯胺 | CAS号106-47-8 对氯苯胺 | CAS号92-86-4 4,4-二溴联苯 | CAS号540-37-4 对碘苯胺 | CAS号122-66-7 1,2-二苯肼 | CAS号3001-15-8 4,4'-二碘代联苯 | CAS号1227476-15-4 1,2-diphenyldiazene | CAS号7440-66-6 锌标准溶液 | CAS号5730-78-9 4'-氨基-4-联苯基羧酸 | CAS号4854-84-6 4-氨基-4'-氰基联苯 | CAS号398-23-2 4,4'-二氟联苯 | CAS号366-29-0 N,N,N',N'-四甲基联苯胺 | CAS号92-86-4 4,4-二溴联苯 | CAS号92-88-6 4,4'-二羟基联苯 | CAS号206182-66-3 (4'-AMINO-BIPHE... | CAS号97-02-9 2,4-二硝基苯胺 | CAS号787-69-9 4,4'-二乙酰联苯 | CAS号2761-22-0 1,1'-Biphenyl,4...1,2-二苯肼置于盐酸体系中,用 乙醇 作为反应溶剂,化学反应 2.5H,以51%的收率获得产物联苯胺
参考文献:1-Phenyl-1H-Pyrrole-2,5-Dicarboxylic Acid Derivatives As Versatile Hydrogen-Bonding Motifs For The Formation Of One-,Two-And Three-Dimensional Networks In The Solid State †
标题:1-Phenyl-1H-Pyrrole-2,5-Dicarboxylic Acid Derivatives As Versatile Hydrogen-Bonding Motifs For The Formation Of One-,Two-And Three-Dimensional Networks In The Solid State †
摘要:制备了一系列1-苯基-1H-吡咯-2,5-二羧酸衍生物,并研究了它们的固态结构.单体亚单元的微小结构变化会导致形成一维线性带状,二维片层和三维网络结构.在每种情况下,固态结构的共同特点是相邻吡咯亚单元的2,5-羧酸基团之间形成双齿氢键相互作用.晶体排列的确切性质受到苯环上取代基的强烈影响.
DOI:10.1039/a803966F
专利信息
专利号:US-5977301-A
优先权日:1992-09-24
标题 :Synthesis of N-substituted oligomers
发明人:ZUCKERMAN RONALD N; KERR JANICE M; KENT STEPHEN B H; MOOS WALTER H; SIMON REYNA J; GOFF DANE A
权利人:CHIRON CORP
摘要:A solid-phase method for the synthesis of N-substituted oligomers, such as poly (N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a resin-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability.
专利号:US-2012130699-A1
优先权日:2010-11-22
标 题 :Method of molecular design and synthesis of therapeutic and preventive drugs
发明人:MARTYNOV ARTUR; FARBER BORIS S; FARBER SONYA SOPHYA
权利人:MARTYNOV ARTUR; FARBER BORIS S; FARBER SONYA SOPHYA
摘要:Industrial Application: This invention may be used in human and veterinary medicine for the design (creation and synthesis) of therapeutic and preventive drugs that are effective for the treatment of oncological and viral human and animal illnesses and for the design of new medicines. n Summary of the Invention: A new method of design and synthesis of therapeutic and preventive drugs in which a biopolymer target (protein, DNA, RNA, or a mixture of these) is used, and in the capacity of a ligand, the same biopolymer target is used, which is cut into oligomer fragments (nucleases, synthetic nucleases, and proteases); the fragments are modified through changing their charges to the opposite charge (acylation of anhydrides of dicarbonate acids or alkylation with halogen-carbonic acids). Also in the capacity of a ligand, the same biopolymer target is used, which is modified by partially changing the molecules' charges to the opposite with the creation of supramolecular biopolymer assemblies. We used supramolecule assemblies made from oligomers that were products of the hydrolysis of biopolymers, but with a change of the charge of the molecules to the opposite charge, as well as the partial change of the charges of the target biopolymers. n Technical Result: A method of molecular design and synthesis of new, unique therapeutic and preventive drugs based on self-organizing systems. The application of the method will allow a significant cut to expenditures on the design and synthesis of new drugs, expand the activity spectra of existing protein gene-engineered drugs, and create new classes of dynamic therapeutic and preventive drugs that self-adapt to the organism and target.
专利号:EP-0671928-B1
优先权日:1992-09-24
标题 :Synthesis of n-substituted oligomers
发明人:ZUCKERMANN RONALD N; KERR JANICE M; KENT STEPHEN BRIAN HENRY; MOOS WALTER H; SIMON REYNA J; GOFF DANE A
权利人:CHIRON CORP
摘要:Poly N-substituted Glycines (poly NSGs), wherein the substituents bear purine or pyrimidine bases (R<9>) every second glycine: In addition, a solid phase method for the synthesis of N-substituted oligomers of more general structures is disclosed.The poly NSGs obtainable by this method can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a resin-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using the automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability.
专利号:US-5877278-A
优先权日:1992-09-24
标题:Synthesis of N-substituted oligomers
发明人:ZUCKERMANN RONALD N; GOFF DANE A; NG SIMON; SPEAR KERRY; SCOTT BARBARA O; SIGMUND AARON C; GOLDSMITH RICHARD A; MARLOWE CHARLES K; PEI YAZHONG; RICHTER LUTZ; SIMON REYNA
权利人:CHIRON CORP
摘要:A solid-phase method for the synthesis of N-substituted oligomers, such as poly (N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a solid support-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability. Combinatorial libraries of cyclic compounds are disclosed wherein the cyclic compounds are comprised of at least one ring structure derived from cyclization of a peptoid backbone. The diversity of product compounds is generated by the sequential addition of substituted submonomers. The combinatorial library includes 10 or more, preferably 100 or more, and more preferably 1,000 or more distinct and different compounds. The library includes each of the product compounds in retrievable and analyzable amounts and preferably includes at least one biologically active compound. Methods of synthesizing the combinatorial libraries and assay devices produced using the libraries are disclosed as is methodology for screening for and obtaining biologically active cyclic organic compounds.
专利号:US-2023183177-A1
优先权日:2020-04-24
标题:Enantioselective chemo-enzymatic synthesis of optically active amino amide compounds
发明人:GRILL BIRGIT; WINKLER MARGIT; SCHWAB HELMUT; STROHMEIER GERNOT; DONSBACH KAI; WALDVOGEL SIEGFRIED R; ARNDT SEBASTIAN; WEIS DOMINIK
权利人:PHARMAZELL GMBH
摘要:The present invention relates to a novel biocatalytic process for the stereoselective preparation of alpha amino amide compounds catalyzed by NHase enzymes. A further aspect of the invention relates to novel NHase enzymes as well as further improved NHase enzyme mutants, nucleic acid molecules encoding these enzymes, recombinant microorganisms suitable for preparing such enzymes and mutants. Another aspect of the invention relates to a chemo-biocatalytic process for the preparation of lactam compounds comprising the new catalytic process for the preparation of alpha amino amide compounds catalyzed by NHase enzymes, as well as the chemical oxidation of the alpha amino amide by applying certain chemical oxidation catalysts suitable for converting the alpha amino amide under retention of its stereochemical configuration to the respective lactam. The novel chemo-biocatalytic process is particularly suited for the synthesis of valuable pharmaceutical compounds, like in particular (S)-Levetiracetam.
专利号:US-2013338369-A1
优先权日:2011-03-07
标 题 :Process for the Synthesis of Aminobiphenylene
发明人:HEINRICH MARKUS; PRATSCH GERALD
权利人:HEINRICH MARKUS; PRATSCH GERALD; BASF SE
摘要:The present invention relates to a process for the synthesis of 2-aminobiphenylene and derivatives thereof by reacting a benzene diazonium salt with an aniline compound under basic reaction conditions.